OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Pishvaian Discusses Progress in Pancreatic Cancer

December 5th 2017

Michael Pishvaian, MD, PhD, discusses the progress that has been made in the treatment of patients with pancreatic cancer during the 2017 Ruesch Center Symposium.

Dr. Marshall Discusses the State of RAS Mutations in GI Cancers

December 5th 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the current state of RAS-mutant gastrointestinal (GI) cancers during the 2017 Ruesch Center Symposium.

Dr. McCollum Discusses Immunotherapy in CRC

December 2nd 2017

A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses integrating immunotherapy into the treatment landscape of colorectal cancer (CRC).

Dr. Mikhail on Ongoing Trials in Multiple Myeloma

December 2nd 2017

Sameh Mikhail, MD, medical oncologist, The Mark H. Zangmeister Cancer Center, discussing ongoing trials for patients with multiple myeloma.

Dr. Zhang on the ARCHES Trial in Prostate Cancer

December 1st 2017

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES study for patients with prostate cancer.

Dr. Gordon on Clinical Trials in Hodgkin Lymphoma

December 1st 2017

Leo I. Gordon, MD, a professor of medicine at Feinberg School of Medicine, Northwestern University, discusses clinical trials in Hodgkin lymphoma.

Dr. Harrison on Choosing Frontline Treatment for RCC

December 1st 2017

Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses choosing frontline treatment for patients with renal cell carcinoma (RCC).

Dr. Friedlander on Checkpoint Inhibitors in the Second-Line Setting of Bladder Cancer

November 30th 2017

Terence Friedlander, MD, an assistant clinical professor in the Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses checkpoint inhibitors in the second-line setting for patients with bladder cancer.

Dr. Sabbatini on Novel Approaches With IP Therapy For Ovarian Cancer

November 30th 2017

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses novel approaches for IP therapy for patients with ovarian cancer.

Dr. Atkinson on Novel Combinations in Melanoma

November 30th 2017

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses novel combinations for the treatment of patients with melanoma.

Dr. Luke on the Clinical Trial Landscape for Melanoma

November 29th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the clinical trial landscape for melanoma

Dr. Yardley on BOLERO-2 Results for HR+ Breast Cancer

November 29th 2017

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the BOLERO-2 results for patients with hormone receptor (HR)-positive breast cancer.

Dr. Kim on the Importance of Biomarker Testing for Lung Cancer

November 29th 2017

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the importance of biomarker testing in lung cancer.

Dr. Bendell on the Treatment of Microsatellite Stable Patients With CRC

November 28th 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the treatment of patients with colorectal cancer (CRC) that are microsatellite stable.

Dr. Pusztai on Challenges With Neoadjuvant HER2 Therapy

November 28th 2017

Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center and Yale School of Medicine, discusses the challenges facing neoadjuvant treatment of patients with HER2-positive breast cancer

Dr. Young on the Challenges of Using Anticoagulants in Children With Cancer

November 28th 2017

Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, discusses the challenges of using anticoagulants in children with cancer.

Dr. Haldorsen Discusses the Challenges With Imaging in Endometrial Cancer

November 28th 2017

Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, discusses the challenges with imaging in endometrial cancer.

Dr. Hendifar Discusses a 92-Gene Assay of NETs

November 28th 2017

Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses a 92-gene assay of patients with neuroendocrine tumors (NETs).

Dr. Gainor Discusses the Future of EGFR+ NSCLC

November 28th 2017

Justin F. Gainor, MD, assistant professor of medicine, Harvard Medical School, attending physician, Massachusetts General Hospital, discusses the future of treatment for patients with EGFR-positive non-small cell lung cancer.

Dr. Dottino on Targeted Therapies in Ovarian Cancer

November 28th 2017

Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses targeted therapies for patients with ovarian cancer.